Jun 19, 2019   SOURCE: PR NewsWire

Global Opioid-Induced Constipation Market 2019: Two Orphans and an Avastin Biosimilar Among EU Approval Recommendations

DUBLIN, June 19, 2019 /PRNewswire/ -- The "Market Spotlight: Opioid-Induced Constipation" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This Market Spotlight report covers the Opioid-Induced Constipation market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, patent information, probability of success, epidemiology data, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts

Key Takeaways

    --  The approved drugs in the opioid-induced constipation (OIC) space
        predominantly target opioid receptors, with the exception of Amitiza, a
        type-2 chloride channel activator. All of the marketed drugs are
        administered via the oral route, with one product also being available
        in a subcutaneous formulation.
    --  The majority of industry-sponsored drugs in active clinical development
        for OIC are in Phase II, with only one drug in Phase III. Therapies in
        mid-to-late-stage development for OIC target opioid receptors and
        guanylyl cyclase c receptor. These therapies are administered via the
        oral route.
    --  The overall likelihood of approval of a Phase I gastroenterology (non
        inflammatory bowel disease)-other asset is 22.5%, and the average
        probability a drug advances from Phase III is 66.7%. Drugs, on average,
        take 10.1 years from Phase I to approval, compared to 9.9 years in the
        overall gastroenterology (non inflammatory bowel disease) space.
    --  The clinical trials distribution across Phase I-IV indicates that the
        majority of trials for OIC have been in the late phases of development,
        with 61% in Phase III-IV, and only 39% in Phase I-II.
    --  Clinical trial activity in the OIC space is dominated by completed
        trials. Shionogi has the highest number of completed trials for OIC,
        with nine trials.
    --  Shionogi leads the industry sponsors with the highest number of clinical
        trials for OIC, followed by Pfizer

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT
Management of OIC with laxatives
Management of OIC with opioid antagonists
Management of OIC with Amitiza, a secretagogue chloride channel activator

EPIDEMIOLOGY
Recent prevalence studies
Challenges

MARKETED DRUGS

PIPELINE DRUGS

KEY REGULATORY EVENTS
Two Orphans And An Avastin Biosimilar Among EU Approval Recommendations
CHMP Delays Review of Portola's Ondexxya; Who Will Pass Muster?

PROBABILITY OF SUCCESS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase

BIBLIOGRAPHY
Prescription information

For more information about this report visit https://www.researchandmarkets.com/r/g8y6la

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-opioid-induced-constipation-market-2019-two-orphans-and-an-avastin-biosimilar-among-eu-approval-recommendations-300871245.html

SOURCE Research and Markets